ALGS - Aligos Therapeutics, Inc.
Previous close
42.62
-0.420 -0.985%
Share volume: 1,927
Last Updated: Thu 26 Dec 2024 08:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$43.04
-0.42
-0.98%
Fundamental analysis
24%
Profitability
25%
Dept financing
10%
Liquidity
73%
Performance
15%
Performance
5 Days
1.26%
1 Month
84.26%
3 Months
390.52%
6 Months
9,735.00%
1 Year
5,230.62%
2 Year
4,224.98%
Key data
Stock price
$42.62
DAY RANGE
$39.05 - $43.04
52 WEEK RANGE
$0.38 - $42.95
52 WEEK CHANGE
$5,886.91
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Lawrence M. Blatt
Region: US
Website: www.aligos.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: www.aligos.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB)
Recent news